Related Experiment Video
Updated: May 6, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Image-Based Phenotypic Profiling Enables Rapid and Accurate Assessment of EGFR-Activating Mutations in Tissues from
Qian Lei1,2,3, Xinglong Zhou4, Ying Li1,2,3
1Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610065, China.
Abstract:
Determining mutations in the kinase domain of the epidermal growth factor receptor (EGFR) is critical for the effectiveness of EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. Yet, DNA-based sequencing analysis of tumor samples is time-consuming and only provides gene mutation information on EGFR, making it challenging to design effective EGFR-TKI therapeutic strategies. Here, we present a new image-based method involving the rational design of a quenched probe based on EGFR-TKI to identify mutant proteins, which permits specific and "no-wash" real-time imaging of EGFR in living cells only upon covalent targeting of the EGFR kinase. We also show that the probe enables distinguishing EGFR mutant tumor-bearing mice from wild-type tumor-bearing mice via fluorescence-intensity-based imaging with high signal contrast. More interestingly, the image-based phenotypic approach can be used to predict EGFR mutations in tumors from lung cancer patients with an accuracy of 94%. Notably, when immunohistochemistry analysis is integrated, an improved accuracy of 98% is achieved. These data delineate a drug-based phenotypic imaging approach for in-biopsy visualization and define functional groups of EGFR mutants that can effectively guide EGFR-TKI therapeutic decision-making besides gene mutation analysis.
Insights
A novel imaging probe identifies epidermal growth factor receptor (EGFR) mutations in lung cancer cells and tumors. This drug-based approach offers a faster, more accurate method for guiding EGFR tyrosine kinase inhibitor (TKI) therapy.
Area of Science:
- Biomedical Imaging
- Molecular Oncology
- Drug Discovery
Background:
- Accurate identification of epidermal growth factor receptor (EGFR) mutations is crucial for effective EGFR tyrosine kinase inhibitor (TKI) therapy in lung cancer.
- Current DNA sequencing methods are time-consuming and provide limited information, hindering optimal therapeutic strategy design.
Purpose of the Study:
- To develop a novel, image-based method for rapid and specific detection of mutant EGFR proteins.
- To enable real-time visualization and phenotypic assessment of EGFR mutations in living cells and tumors.
- To guide therapeutic decisions for EGFR-TKI treatment in lung cancer.
Main Methods:
- Rational design of a quenched, covalent-targeting probe based on an EGFR-TKI.
- Application of the probe for "no-wash" real-time imaging of EGFR in living cells.
- Fluorescence-intensity-based imaging to distinguish EGFR mutant from wild-type tumors in mice.
- Integration with immunohistochemistry for enhanced diagnostic accuracy.
Main Results:
- The probe specifically targets and images mutant EGFR in living cells.
- High signal contrast achieved in distinguishing mutant from wild-type tumors in mice.
- Image-based prediction of EGFR mutations in lung cancer patients with 94% accuracy.
- Improved accuracy to 98% when combined with immunohistochemistry.
Conclusions:
- A drug-based phenotypic imaging approach enables in-biopsy visualization of EGFR mutations.
- This method effectively defines functional EGFR mutant groups to guide EGFR-TKI therapy.
- The approach complements traditional gene mutation analysis for personalized lung cancer treatment.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
